Ⅲ期黑色素瘤预后:AJCC第8版分期的再评估
本研究基于CMMR登记(1553例)及EORTC两项研究(18991观察组573例、18071安慰剂组445例)独立队列,比较Ⅲ期黑色素瘤生存与AJCCv8已发表数据。结果显示CMMR与EORTC队列的黑色素瘤特异性生存(MSS)整体低于AJCCv8,尤其ⅢA和ⅢB亚期。
要点
- CMMR队列Ⅲ期5年MSS为67%,低于AJCCv8的77%。
- ⅢA期5年MSS为80% vs 93%,ⅢB期为75% vs 83%。
- EORTC研究MSS与CMMR重叠或更低,提示AJCCv8可能高估预后。
核心结论
- CMMR和EORTC队列的Ⅲ期黑色素瘤MSS整体低于AJCCv8已发表数据,ⅢA和ⅢB亚期尤为明显。
研究设计与样本
- CMMR登记纳入2000–2012年初诊Ⅲ期黑色素瘤患者1553例。
- EORTC 18991研究观察组573例和18071研究安慰剂组445例作为参考队列。
- 生存结局与已发表的AJCCv8Ⅲ期生存数据进行比较。
主要发现
- CMMR队列Ⅲ期5年MSS为67% vs AJCCv8的77%,10年为56% vs 69%。
- ⅢA期5年MSS为80% vs 93%,10年为71% vs 88%。
- ⅢB期5年MSS为75% vs 83%,10年为61% vs 77%。
- EORTC研究的MSS与CMMR数据重叠或更低。
临床怎么用
- 临床评估Ⅲ期黑色素瘤预后时,应知晓AJCCv8可能高估生存,尤其ⅢA和ⅢB期。
- 与患者沟通预后及辅助治疗决策时,可参考CMMR和EORTC队列的较低MSS数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Three new therapies have been approved recently for the adjuvant treatment of stage III melanoma, substantially reducing the risk of tumor recurrences. This study evaluates 3 independent data sets to clarify the survival probabilities of patients with stage III melanoma. PATIENTS AND METHODS: The Central Malignant Melanoma Registry (CMMR) evaluated 1,553 patients with a primary diagnosis of stage III melanoma from 2000 to 2012. Studies from the European Organisation for Research and Treatment of Cancer (EORTC), of 573 patients in the observation arm of the 18991 study and 445 patients in the placebo arm of the 18071 study, were evaluated as reference cohorts. The survival outcomes were compared with the published American Joint Committee on Cancer version 8 (AJCCv8) stage III survival data. RESULTS: For the CMMR stage III cohort versus the AJCCv8 cohort, the melanoma-specific survival (MSS) rates at 5 years were 67% versus 77%, and at 10 years were 56% versus 69%, respectively. For stage IIIA, the MSS rates at 5 years were 80% versus 93%, and at 10 years were 71% versus 88%; for stage IIIB, the MSS rates at 5 years were 75% versus 83%, and at 10 years were 61% versus 77%. The MSS rates of the EORTC studies either overlapped with or were lower than, the CMMR data. CONCLUSION: The MSS rates in the CMMR and EORTC cohorts over the entire stage III are less favorable than those published in AJCCv8. This is particularly true for substages IIIA and IIIB.
引用
- Garbe C, Keim U, Suciu S, et al. Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts. J Clin Oncol. 2020. PMID: 32530760. doi:10.1200/JCO.19.03034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。